演題抄録

一般演題(示説)

開催概要
開催回
第51回・2013年・京都
 

Pazopanib in unresectable/recurrent sarcoma: a single-center case series

演題番号 : P30-6

[筆頭演者]
Naoto Takase:1 
[共同演者]
Takuma Onoe:1、Maki Tanioka:1、Koji Matsumoto:1、Naomasa Fukase:2、Takuya Fujimoto:2、Ikuo Fujita:2、Toshiko Sakuma:3、Shunichi Negoro:1

1:Department of Medical Oncology, Hyogo Cancer Center, Japan、2:Department of Orthopedics, Hyogo Cancer Center, Japan、3:Department of Pathology, Hyogo Cancer Center, Japan

 

Background: In 2012, pazopanib, which is the first molecular target drug for soft tissue sarcoma, was approved. Soft tissue sarcoma is a rare tumor, it accounts for approximately 1% of all adult cancers, and the number of Japanese patients who participated in the clinical trial is only 44 patients. Method: We performed a retrospective review of 8 patients who were treated with pazopanib (800 mg once daily) in our institution. We examined characteristics, treatment duration, effect of treatment, and toxicity. Result: There were 5 men and 3 women, and median age was 63 years (range, 42-67). All patients had PS 0 (2 patients) or 1 (6 patients). The AJCC/UICC stage at presentation was IIB(1), III(5), IV(2). 1 patient was unresectable at presentation, and 7 patients performed surgical resection, and later developed metastases. 2 patients diagnosed as dedifferenciated liposarcoma, 3 patients as leiomyosarcoma, 1 patient as synovial sarcoma, 1 patient as Ewing sarcoma/primitive neuroectodermal tumor, and 1 patient diagnosed as spindle cell tumor (suspicious for sarcoma). Median previous regimen was 2 (1-4 regimen). At May 7, 2013, median duration of treatment was 61.5 (34-118) days, 4 patients failed (All of them were Progressive Disease(PD)), and the others were on going. The effect of treatment was 3 Stable Disease(SD), 4 PD, 1 Not evaluable(NE, waiting for image). For safety, liver dysfunction occured in 4 patients (All of them were Grade 3), hypertension in 4 patients (All of them were Grade 2), nausea in 3 patients, diarrhea in 2 patients, a drop in left venticular ejection fraction in 1 patient (Grade 1), and thrombocytopenia in 1 patient (Grade 2). Conclusions: Incidence of liver dysfunction(50%) was higher than the clinical trial, and thrombocytopenia, which was not experienced in the clinical trial, developed in 1 patient.

キーワード

臓器別:骨軟部

手法別:分子標的治療

前へ戻る